*Again, why didn't Trump take it? Why do we keep hearing about Regeneron?* *MCM*
*From Josh Mitteldorf:* *It's a small sample, but hospitalization rate for HCQ+Zn is 1/6 compared to a control group.* *https://www.sciencedirect.com/science/article/pii/S0924857920304258?via%3Dihub <https://www.sciencedirect.com/science/article/pii/S0924857920304258?via%3Dihub>* > ---------- Forwarded message --------- > From: Zev Zelenko <[email protected]> > Date: Tue, Oct 27, 2020 at 1:33 PM > Subject: Immediate Release: Groundbreaking Study Accepted for Publication > by The International Journal of Antimicrobial Agents > To: Zev Zelenko <[email protected]> > > > Check our this link for further information on The Internet Protocol: > https://internetprotocol.co/hype-news/2020/10/27/a-study-by-dr-zelenko-was-accepted-for-publication/ > > *If you would like to publish this press release, we would appreciate if > you could indicate that you received this material from The Internet > Protocol.* > > B”H > Groundbreaking Study Accepted for Publication by The International > Journal of Antimicrobial AgentsData Based On Zelenko Protocol Passes Peer > Review COVID-19 Outpatients - Early Risk-Stratified Treatment with Zinc > plus Low-Dose Hydroxychloroquine and Azithromycin: A Retrospective Case > Series Study > > By Roland Derwand > <https://sciprofiles.com/profile/author/MzE5V1hLeVBDeEZlajdVUm56eDdOWERoYXlNNzVGTkYxeGZOVWUra1dxZz0=>, > Martin Scholz, Vladimir Zelenko > <https://sciprofiles.com/profile/author/YkIySFZWWU1hS0hFNUpmQllSK2REcXhKOXFLV0ZqZVNaL25yTTZoN2ovQT0=> > > Conclusion: Early treatment of COVID-19 in high risk patients with “The > Zelenko Protocol” decreased hospitalizations by 84% and resulted in a 5 > fold reduction in death. > > New York, NY. October 27, 2020 – Dr. Vladimir Zelenko and team announced > today that a retrospective study analyzing his patient data was accepted > for publication after a rigorous peer review process.1 The study finds > that early intervention and treatment of high-risk patients with COVID-19 > resulted in significantly fewer hospitalizations and deaths. The treatment > consisting of zinc, low-dose hydroxychloroquine and azithromycin, is also > referred to as “The Zelenko Protocol.” > > This study is unique because only HIGH RISK out-patients were treated with > the triple-drug regimen. High-risk patients are those that have a 5% to > 10% chance of dying from COVID-19. This category includes patients who are > older than 60, who are younger than 60 but have other medical issues, or > who have trouble breathing. All identified high-risk outpatients were > treated at their initial visit, most within the first five days of the > onset of symptoms. All of these patients had laboratory confirmation of > COVID-19 infection. > > The results show that in 141 high risk patients who were treated in the > prehospital setting with the triple therapy, only 2.8% (4/141) were > hospitalized compared to 15.4% of an untreated control group (58/377) (odds > ratio 0.16, 95% CI 0.06-0.5; p<0.001). Only 0.71% (1/141) patients died in > the treatment group, versus 3.5% (13/377) in the untreated group (odds > ratio 0.2, 95% CI 0.03-1.5; p=0.12). > > This retrospective analysis is the product of the unique collaboration of > three doctors with a rare synergy of industry, academia and clinical > medicine. Dr. Roland Derwand is a German physician and life science > industry expert. Professor Martin Scholz is an independent consultant and > adjunct professor for experimental medicine at Heinrich Heine University, > Düsseldorf, Germany. Drs. Derwand and Scholz were the first to draw > attention to “The Zelenko Protocol” in their published hypothesis paper > about the importance of combining zinc with hydroxychloroquine as a method > for treating COVID-19. > > “What differentiates this study is that patients were diagnosed very early > with COVID-19 in an outpatient setting, and only high-risk patients were > treated early on,” said Dr. Derwand. “Unfortunately, we seem to have > forgotten common medical knowledge - that we want to treat any patient with > an infectious disease as soon as possible. Dr. Zelenko treated his > high-risk patients immediately with the three drug regimen to ensure > sufficient efficacy. He correctly didn’t wait for the disease to further > develop.” > > Following the rigorous peer review process, Dr. Zelenko said: “It’s > unfortunate that much of the media coverage surrounding hydroxychloroquine > has been negative. These three medications are affordable, available in > pill form, and work in synergy against COVID-19.” According to Dr. Zelenko: > “Hydroxychloroquine’s main role is to allow zinc to enter the cell and > inhibit the virus’ reproduction. And azithromycin prevents secondary > bacterial infection in the lungs, and reduces the risk of pulmonary > complications.” > > The third author, Professor Scholz added: “This is the first study with > COVID-19 outpatients that shows how a simple-to-perform outpatient risk > stratification allows for rapid treatment decisions shortly after onset of > symptoms. The well-tolerated 5-day triple therapy resulted in a > significantly lower hospitalization rate and less fatalities with no > reported cardiac side effects compared with relevant public reference data > of untreated patients. The magnitude of the results can substantially > elevate the relevance of early use, low-dose hydroxychloroquine, especially > in combination with zinc. This data can be used to inform ongoing pandemic > response policies as well as future clinical trials.” > > Especially as vaccines will still not be available during the currently > ongoing second wave of the pandemic a broader use of the Zelenko protocol > to treat positively risk stratified COVID-19 outpatients as early as > possible seem to represent a so far underestimated additional option to win > today's battle against COVID-19. > > > > 1. > > Derwand, R., Scholz, M., Zelenko, V. COVID-19 outpatients – early > risk-stratified treatment with zinc plus low dose hydroxychloroquine and > azithromycin: a retrospective case series study. Int. J. Antimicrob. > Agents, available online 26 October 2020, > https://doi.org/10.1016/j.ijantimicag.2020.106214 > > > About Dr. Roland Derwand > > Based in Munich, Derwand is a medical doctor and life science industry > expert with almost 20 years of experience. He currently heads the medical > affairs department of a U.S. biotech company in Germany. His engagement and > contribution to this study has been private and independent. Before he held > various positions in the pharma and biotech industry with national, > European and global responsibilities. He holds an M.D. from Johannes > Gutenberg University in Mainz, Germany, an MBA from the PFH Private > University of Applied Sciences in Göttingen, Germany, and he did his > doctorate in cardiovascular physiology. > > About Professor Dr. Martin Scholz > > Scholz holds a doctorate degree (Ph.D.) from Johann Wolfgang Goethe > –University, Frankfurt am Main, Germany and is an adjunct professor for > experimental medicine at Heinrich Heine University Düsseldorf. He also > serves as managing director of the “Starts- and -Ups Consulting” company. > Prior to this, Scholz served as the chief scientific officer on the > executive board of LEUKOCARE AG, a biotech company he founded in 2001. > Scholz received the title “professor honoris causa” at the Faculty of > Medicine Marilia (FAMEMA) in São Paulo, Brasil. > > > About Dr. Vladimir Zelenko > > Zelenko graduated from SUNY at Buffalo School of Medicine in 2000. He is > Board Certified in Family Medicine with 20 years of clinical experience. > > --- Support News from Underground: https://bit.ly/NFUSupport Visit News from Underground: https://markcrispinmiller.com You received this email because you are subscribed to News from Underground. To unsubscribe from this email list, please go to: http://www.simplelists.com/confirm.php?u=pIdjNUgiG2h8yxbhC54SSy4SEskAoEMs For archives, please go to: https://archives.simplelists.com/nfu
